Pharma channel feed – Endpoints News

Pharma channel feed

Allergan buys an ailing Repros, bagging a women’s health drug for the pipeline

8 years ago

In latest blow to Eli Lilly, Sanofi wins FDA OK for Humalog me-too

8 years ago

Activists threaten to push for a sale of Alexion if execs can't jack up stock price

8 years ago

Taking on gamma delta T cells, bluebird pays $16M for TC BioPharm's tumor invading tech platform

8 years ago

Alexion lines up $40M upfront deal with Halozyme to develop a better, easier next-gen followup to Soliris

8 years ago

Juno inks deals with Eli Lilly, the Hutch as it looks to leapfrog leaders on BCMA

8 years ago

Cancer R&D tips the scales at the FDA as active INDs climb to record high

8 years ago

Clinical trial transparency improves at (some) biopharmas as J&J, Sanofi lead a pack trailed by Valeant and Allergan

8 years ago

Merck and PhRMA to FDA: Wait for ICH before finalizing guidance on toxicity testing for cancer drugs

8 years ago

In a blow to Eli Lilly, Novo Nordisk lands FDA OK for their next big entry in the diabetes market: Ozempic

8 years ago

Philippine health officials order Sanofi to halt Dengvaxia sales as controversy over health threat swells

8 years ago

J&J adds PhIII hypertension drug to the pipeline with $230M-plus cash deal for Idorsia

8 years ago

Astellas forges a $390M deal to buy a biotech focused on Ronald Evans’ ‘exercise-in-a-pill’ tech

8 years ago

What's killing patients in Bayer's Xofigo combo study? Researchers unblind study early to probe safety alert

8 years ago

Indivior tightens grip on opioid addiction market with Sublocade's new FDA approval

8 years ago

Cures Act implementation: Gottlieb says faster cancer drug approvals coming for secondary indications

8 years ago

Major deregulation? FDA withdraws several rules and regulations related to medical products

8 years ago

After all the love and money, analysts speculate that J&J may swoop in with a buyout offer for Genmab

8 years ago

In latest deal, Melinta executes $270M pact to buy out Medicines Co’s infectious disease group

8 years ago

Regeneron and Decibel aren’t just collaborating: They want to create a whole new partnering model

8 years ago

How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash

8 years ago

Roiled by financial turmoil, Teva's CEO boots R&D chief, top execs in C-suite overhaul

8 years ago

Biogen’s answer to Alkermes’ Tecfidera threat? Buy it, but don’t spend too much

8 years ago

Merck blueprints $1.3B research hub in a post-Brexit London, with 950 staffers

8 years ago

First page Previous page 311 312 313314315 316 317 Next page Last page